Brian Park, PharmD

All articles by Brian Park, PharmD

Breast Cancer News

Enhertu Approved to Treat HER2-Positive Breast Cancer Following 2 or More Prior Anti-HER2 Therapies

By

Brian Park, PharmD

December 27, 2019

Results showed a confirmed ORR of 60.3% including a 4.3% complete response rate and 56.0% partial response rate, with a median DOR of 14.8 months.

Gastrointestinal Cancers

Microbiome-Derived Therapy Gets Orphan Drug Status for Hepatocellular Carcinoma

By

Brian Park, PharmD

October 28, 2019

SFA001 blocked the progression of hepatitis B to HCC in transgenic HBX animal models

Next post in Gastrointestinal Cancers

SIRT plus FOLFOX significantly delayed tumor progression in the liver, but did not improve overall p

PHGDH Identified as a Potential Target to Overcome Sorafenib Resistance in HCC